← Back to Clinical Trials
Recruiting NCT07429305

NCT07429305 Combined Tibial Nerve Stimulation and Standing for People With SCI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07429305
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Spinal Cord Injury
Study Type INTERVENTIONAL
Enrollment 12 participants
Start Date 2026-04-02
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Standing + Tibial Nerve Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 12 participants in total. It began in 2026-04-02 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to understand how sensory inputs from the lower leg can influence pelvic floor muscle function and urogential function in adults with chronic spinal cord injury (SCI). The main questions it aims to answer are: 1. What is the modulatory role of load and posture on reflex activation of the pelvic floor muscles in participants with SCI? 2. What is the feasibility of combining tibial neuromodulation with standing therapy in participants with SCI? 3. What are the potential effects of combined tibial neuromodulation and standing therapy on reflex excitability and urogential symptoms and quality of life in people with SCI? Participants will be asked complete a series of assessments (questionnaires, electrophysiological testing) before and after a 12-week intervention of combined standing and tibial nerve stimulation therapy.

Eligibility Criteria

Inclusion Criteria: * At least 19 years of age * Have a SCI between C7 - T10 that occurred at least 12 months previously * Have a motor-complete or incomplete SCI (AIS A, B, C, or D) * Have symptoms of neurogenic LUT dysfunction * Meet the manufacture requirements for standing frame use (will be evaluated by the research team) * Are able to speak and understand English. Exclusion Criteria: * Have changed their bladder management program in the past month * Have received an injection of Botulinum toxin-A in any LUT structure in the past 2 weeks, or intend to receive an injection while participating in the trial * Have a non-stable SCI (e.g. spinal tumor) * Have signs of a lower motoneuron injury (e.g. cauda equina syndrome) * Have other neurological injury besides SCI * Have an implanted metallic or electronic device (e.g. pace maker, nerve stimulator) * Have a condition for which exercise or transcutaneous stimulation is contraindicated * Have a severe acute medical issue that in the investigator's judgement would adversely affect the participant's participation in the study. Examples include, but are not limited to acute urinary tract infections, pressure sores, musculoskeletal injury, or unmanage blood pressure. * Are currently pregnant or have given birth within the past 12 months * Use walking as your primary means of movement around your home and the community.

Contact & Investigator

Central Contact

Yao Sun, PhD

✉ lamlab@icord.org

📞 604-675-8815

Frequently Asked Questions

Who can join the NCT07429305 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07429305 currently recruiting?

Yes, NCT07429305 is actively recruiting participants. Contact the research team at lamlab@icord.org for enrollment information.

Where is the NCT07429305 trial being conducted?

This trial is being conducted at Vancouver, Canada.

Who is sponsoring the NCT07429305 clinical trial?

NCT07429305 is sponsored by University of British Columbia. The trial plans to enroll 12 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology